Corcept Therapeutics (CORT) Expected to Announce Earnings on Tuesday

Corcept Therapeutics (NASDAQ:CORT) is projected to issue its Q4 2025 results after the market closes on Tuesday, February 24th. Analysts expect the company to announce earnings of $0.27 per share and revenue of $254.9370 million for the quarter. Parties can find conference call details on the company’s upcoming Q4 2025 earning report page for the latest details on the call scheduled for Tuesday, February 24, 2026 at 5:00 PM ET.

Corcept Therapeutics Trading Up 1.7%

NASDAQ CORT opened at $34.82 on Friday. The firm has a market capitalization of $3.66 billion, a PE ratio of 39.57 and a beta of 0.25. The stock’s 50 day moving average is $49.14 and its 200 day moving average is $66.98. Corcept Therapeutics has a twelve month low of $28.66 and a twelve month high of $117.33. The company has a quick ratio of 3.07, a current ratio of 3.14 and a debt-to-equity ratio of 0.01.

Corcept Therapeutics News Roundup

Here are the key news stories impacting Corcept Therapeutics this week:

• Positive Sentiment: HC Wainwright kept a “buy” rating on CORT despite cutting its price target from $105 to $67, signaling some analyst conviction in upside even after the patent loss. The Fly
• Positive Sentiment: Commentary arguing that the recent negative patent news may be largely priced in and that Corcept’s potential upside from ovarian cancer and other pipeline opportunities remains under-appreciated — a bullish narrative some investors are using to buy the dip. Seeking Alpha
• Neutral Sentiment: Reported short interest data in recent filings show effectively zero reported short interest (odd reporting artifact). Low measured short interest reduces immediate short‑squeeze risk but data may be unreliable. (No external link provided.)
• Negative Sentiment: The U.S. Court of Appeals (Federal Circuit) found Teva’s proposed generic does not infringe two Corcept patents covering Korlym, a ruling Corcept disclosed on Feb. 19 — the primary catalyst for the sharp selloff and heightened volatility. Business Wire
• Negative Sentiment: Immediate market reaction included steep intraday declines reported across outlets and several Limit Up/Limit Down (LULD) trading halts as the news hit, signaling heavy selling pressure and elevated short‑term risk. Benzinga

Analysts Set New Price Targets

A number of research firms have recently weighed in on CORT. Wolfe Research downgraded shares of Corcept Therapeutics from a “peer perform” rating to an “underperform” rating and set a $30.00 target price on the stock. in a research report on Wednesday, December 31st. Weiss Ratings restated a “hold (c)” rating on shares of Corcept Therapeutics in a report on Monday, December 29th. HC Wainwright lowered their target price on shares of Corcept Therapeutics from $105.00 to $67.00 and set a “buy” rating for the company in a report on Friday. Zacks Research cut Corcept Therapeutics from a “hold” rating to a “strong sell” rating in a research report on Tuesday, January 13th. Finally, Canaccord Genuity Group raised their price objective on Corcept Therapeutics from $99.00 to $100.00 and gave the company a “buy” rating in a research report on Friday, January 23rd. Four equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and two have given a Sell rating to the company. According to MarketBeat.com, Corcept Therapeutics presently has a consensus rating of “Hold” and a consensus target price of $77.17.

Insider Activity

In related news, insider Sean Maduck sold 20,000 shares of the business’s stock in a transaction that occurred on Monday, December 1st. The shares were sold at an average price of $79.52, for a total value of $1,590,400.00. Following the completion of the transaction, the insider directly owned 7,904 shares in the company, valued at $628,526.08. The trade was a 71.67% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Joseph K. Belanoff sold 40,000 shares of the stock in a transaction on Monday, December 1st. The shares were sold at an average price of $79.77, for a total value of $3,190,800.00. Following the sale, the chief executive officer owned 2,701,370 shares in the company, valued at approximately $215,488,284.90. This represents a 1.46% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 129,500 shares of company stock worth $8,665,500 over the last three months. 20.80% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Corcept Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the company. Pathstone Holdings LLC grew its holdings in shares of Corcept Therapeutics by 0.8% in the third quarter. Pathstone Holdings LLC now owns 18,013 shares of the biotechnology company’s stock worth $1,497,000 after acquiring an additional 144 shares during the period. Gould Capital LLC boosted its position in Corcept Therapeutics by 50.0% in the third quarter. Gould Capital LLC now owns 600 shares of the biotechnology company’s stock worth $50,000 after purchasing an additional 200 shares during the last quarter. Deutsche Bank AG grew its stake in shares of Corcept Therapeutics by 3.4% during the 4th quarter. Deutsche Bank AG now owns 8,446 shares of the biotechnology company’s stock valued at $294,000 after purchasing an additional 279 shares during the period. Advisory Services Network LLC bought a new stake in shares of Corcept Therapeutics during the 3rd quarter valued at about $25,000. Finally, CIBC Private Wealth Group LLC increased its position in shares of Corcept Therapeutics by 128.5% during the 3rd quarter. CIBC Private Wealth Group LLC now owns 770 shares of the biotechnology company’s stock valued at $64,000 after purchasing an additional 433 shares during the last quarter. 93.61% of the stock is owned by institutional investors.

Corcept Therapeutics Company Profile

Corcept Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing drugs that modulate the effects of cortisol, a hormone implicated in a range of severe metabolic, oncologic and psychiatric disorders. The company’s scientific platform centers on selectively targeting the glucocorticoid receptor to counteract the harmful consequences of excess cortisol, a strategy designed to address diseases with significant unmet medical needs.

The company’s flagship marketed product, Korlym (mifepristone), is approved in the United States for the treatment of hyperglycemia secondary to Cushing’s syndrome in patients who have type 2 diabetes or glucose intolerance and are not candidates for surgery.